A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
暂无分享，去创建一个
J. Sludden | Y. Drew | D. Jamieson | A. Boddy | R. Plummer | M. Ranson | U. Banerji | R. Allen | A. Greystoke | E. Dean | K. Swales | A. Anthoney | T. Evans | P. Bevan | M. Griffin | N. Cresti | V. Coyle | R. Wilson | C. Mala | L. Rodgers | Mark Merriman | M. Buerkle